| 摘要 |
The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic). |
| 主权项 |
1. A compound represented by formula II: or a pharmaceutically acceptable salt thereof, wherein:
A is selected from an optionally substituted phenyl ring or an optionally substituted pyridyl ring; andAr is phenyl, pyridyl, or a 5 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur,wherein A and Ar are optionally and independently substituted with one or more R1 substituents;each R1 is independently selected from the group of F, Cl, Br, I, —NO2, —CN, —N3, or -L1-R;R is optionally substituted C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, haloalkyl, phenyl, a 3-7 membered saturated or partially unsaturated cycloalkyl ring, an 8-10 membered bicyclic saturated, partially unsaturated or aryl carbocyclic ring, a 4-7-membered saturated or partially unsaturated heterocycloalkyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;L1 is a covalent bond or an optionally substituted bivalent C1-6 hydrocarbon chain, wherein one or more methylene units of L1 is optionally and independently replaced by -Cy-, —o—, —S—, —N(Ra)—, —C(O)—, —C(S)—, —C(O)N(Ra)—, —N(Ra)C(O)N(Ra)—, —N(Ra)C(O)—, —N(Ra)C(O)O—, —OC(O)N(Ra)—, —S(O)—, —S(O)2—, —S(O)2N(Ra)—, —N(Ra)S(O)2—, —OC(O)—, or —C(O)O—;
-Cy- is an optionally substituted bivalent ring selected from a 3-7 membered saturated or partially unsaturated cycloalkylene ring, a 4-7-membered saturated or partially unsaturated heterocycloalkylene ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenylene, a 5-6 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered bicyclic arylene, or an 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;each Ra is independently for each occurrence —H, —R or —C(O)R; andeach R′ and R″ is —H. |
